SCHEMBL13089998

SCHEMBL13089998

O=C(Cc1ccccc1Nc1c(Cl)cccc1Cl)OCCCCON(O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 3/20 0.64
▸ CYP2C9 P11712 2/20 0.64
▸ USP2 O75604 1/20 0.64
▸ LMNA P02545 1/20 0.64
▸ TBXA2R P21731 1/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ PTGS2 P35354 5/20 0.56
▸ PTGS1 P23219 2/20 0.56
▸ AKR1B10 O60218 1/20 0.56
▸ UGT1A9 O60656 1/20 0.56
▸ TRPA1 O75762 1/20 0.56
▸ ABCB11 O95342 1/20 0.56
▸ MT-CO2 P00403 1/20 0.56
▸ ALB P02768 1/20 0.56
▸ CXCL8 P10145 1/20 0.56
▸ UGT1A6 P19224 1/20 0.56
▸ UGT1A1 P22309 1/20 0.56
▸ CXCR1 P25024 1/20 0.56
▸ ADRA1A P35348 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13089795 0.99 TTR (0.63) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL13089885 0.98 TTR (0.64) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL13089839 0.91 PTGS2 (0.60) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL13089883 0.90 TTR (0.63) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL13265744 0.87 TTR (0.59) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL13777334 0.86 TTR (0.67) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL13109322 0.86 TTR (0.67) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL10116869 0.86 TTR (0.70) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL8644035 0.85 TTR (0.69) TTRCYP2C9USP2LMNATBXA2R
SCHEMBL13109332 0.85 TTR (0.65) TTRCYP2C9USP2LMNATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1906938-B1 PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS NICOX SA (FR) 2010-10-20 — — EP disclosed
US-7815933-B2 Self emulsifying drug delivery system NICOX S.A. (FR) 2010-10-19 — — US disclosed
US-20090203759-A1 PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS NICOX SA (FR) 2009-08-13 — — US disclosed
EP-1427392-B1 NEW SELF EMULSIFYING DRUG DELIVERY SYSTEM NICOX SA (FR) 2008-02-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203759-A1 PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS FASN, PTGS1, NOS2 TTR 1495/4885CYP2C9 123/4885USP2 1533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback